PL372316A1 - Inhibitory DPIV oparte na glutaminylu - Google Patents

Inhibitory DPIV oparte na glutaminylu

Info

Publication number: PL372316A1
Authority: PL; Poland
Prior art keywords: dpiv inhibitors; dpiv; sub; glutaminyl based; glutaminyl
Prior art date: 2002-02-28

Application number

PL02372316A

Other languages

English (en)

Inventor

Hans-Ulrich Demuth

Torsten Hoffmann

Ulrich Heiser

Original Assignee

Prosidion Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-28

Filing date

2002-06-27

Publication date

2005-07-11

2002-06-27 Application filed by Prosidion Limited filed Critical Prosidion Limited

2005-07-11 Publication of PL372316A1 publication Critical patent/PL372316A1/pl

Links

125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002500 effect on skin Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)

PL02372316A 2002-02-28 2002-06-27 Inhibitory DPIV oparte na glutaminylu PL372316A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36090902P	2002-02-28	2002-02-28

Publications (1)

Publication Number	Publication Date
PL372316A1 true PL372316A1 (pl)	2005-07-11

Family

ID=23419891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02372316A PL372316A1 (pl)	2002-02-28	2002-06-27	Inhibitory DPIV oparte na glutaminylu

Country Status (26)

Country	Link
US (2)	US6946480B2 (pl)
EP (1)	EP1480961B1 (pl)
JP (1)	JP2005527504A (pl)
KR (1)	KR20040095241A (pl)
CN (1)	CN1622941A (pl)
AT (1)	ATE349435T1 (pl)
AU (1)	AU2002325278A1 (pl)
BG (1)	BG108857A (pl)
BR (1)	BR0215622A (pl)
CA (1)	CA2479812A1 (pl)
CZ (1)	CZ2004973A3 (pl)
DE (2)	DE20220238U1 (pl)
DK (1)	DK1480961T3 (pl)
EA (1)	EA007434B1 (pl)
ES (1)	ES2278944T3 (pl)
HU (1)	HUP0600057A2 (pl)
IL (1)	IL163629A0 (pl)
MX (1)	MXPA04008278A (pl)
NO (1)	NO20044038L (pl)
NZ (1)	NZ534877A (pl)
PL (1)	PL372316A1 (pl)
PT (1)	PT1480961E (pl)
SI (1)	SI1480961T1 (pl)
SK (1)	SK3622004A3 (pl)
UA (1)	UA76309C2 (pl)
ZA (1)	ZA200406813B (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001518290A (ja) *	1997-09-29	2001-10-16	ポイントセラピューティクス，インコーポレイテッド	インビトロでの造血細胞の刺激
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
US20070293426A1 (en) *	2001-04-02	2007-12-20	Hans-Ulrich Demuth	Methods for improving islet signaling in diabetes mellitus and for its prevention
ATE380175T1 (de) *	2001-06-27	2007-12-15	Smithkline Beecham Corp	Pyrrolidine als dipeptidyl peptidase inhibitoren
US20040242568A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
MXPA06001601A (es)	2003-08-13	2006-08-25	Takeda Pharmaceutical	Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
AU2004267955A1 (en) *	2003-09-02	2005-03-10	Prosidion Ltd.	Combination therapy for glycaemic control
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102079743B (zh)	2004-03-15	2020-08-25	武田药品工业株式会社	二肽基肽酶抑制剂
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
EP1794120B1 (en) *	2004-07-23	2012-04-11	Nuada, LLC	Peptidase inhibitors
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
JP2008524331A (ja) *	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MX2007011453A (es)	2005-04-22	2008-02-12	Alantos Pharmaceuticals Holding Inc	Inhibidores de la dipeptidil peptidasa-iv.
NZ566799A (en)	2005-09-14	2011-04-29	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en)	2005-09-16	2007-03-29	Takeda Pharmaceutical Company Limited	Process for the preparation of pyrimidinedione derivatives
CN1979367B (zh) *	2005-11-30	2013-05-15	北京中电华大电子设计有限责任公司	采用测试校准提高器件参数精度的方法
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
NZ571110A (en)	2006-04-11	2011-03-31	Arena Pharm Inc	Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
EP2146210A1 (en)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
SG174974A1 (en) *	2009-03-30	2011-11-28	Dong A Pharm Co Ltd	Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja)	2010-04-06	2013-06-17	アリーナファーマシューティカルズ，インコーポレイテッド	Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
CN102453001B (zh) *	2010-10-22	2016-06-01	中国医学科学院药物研究所	硫代吗啉类化合物及其制备方法和用途
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
CN107683135A (zh)	2015-03-09	2018-02-09	因特克林医疗有限公司	用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE296075C (pl)
US2961377A (en) *	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
DE2009743A1 (de)	1970-03-03	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Substituierte Biguanide mit antihyperglykämischer Wirkung
US3960949A (en) *	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (pl)	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en) *	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en) *	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
DD296075A5 (de) *	1989-08-07	1991-11-21	Martin-Luther-Universitaet Halle-Wittenberg,De	Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
ES2113879T3 (es)	1990-01-24	1998-05-16	Douglas I Buckley	Analogos de glp-1 utiles para el tratamiento de diabetes.
EP0528858B1 (en)	1990-04-14	1997-01-22	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type iv
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
WO1991017767A1 (en)	1990-05-21	1991-11-28	New England Medical Center Hospitals, Inc.	Method of treating inhibition of dipeptidyl aminopeptidase type iv
JPH0819154B2 (ja)	1991-03-14	1996-02-28	江崎グリコ株式会社	ジペプチジルカルボキシペプチダーゼを阻害するペプチド
JPH04334357A (ja)	1991-05-02	1992-11-20	Fujirebio Inc	酵素阻害作用を有するアシル誘導体
CA2121369C (en)	1991-10-22	2003-04-29	William W. Bachovchin	Inhibitors of dipeptidyl-aminopeptidase type iv
IL106998A0 (en) *	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
FR2696740B1 (fr)	1992-10-13	1994-12-30	Dospharma Sa	Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1995011689A1 (en)	1993-10-29	1995-05-04	Trustees Of Tufts College	Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en) *	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) *	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1997045117A1 (en)	1996-05-29	1997-12-04	Prototek, Inc.	Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
AR016751A1 (es)	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
EP1062222A1 (en)	1998-03-09	2000-12-27	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
AU765370B2 (en)	1998-06-05	2003-09-18	Point Therapeutics, Inc.	Cyclic boroproline compounds
DE19826972A1 (de)	1998-06-18	1999-12-23	Univ Magdeburg Tech	Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation
EP1092046A4 (en)	1998-07-02	2003-02-19	Invitro Diagnostics Inc	METHODS, COMPOSITIONS AND DEVICE FOR MANUFACTURING NUCLEIC ACIDS HAVING SELECTIVE AFFINITY FOR A TARGET MOLECULE
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
CA2339537A1 (en)	1998-08-21	2000-03-02	Barbara Wallner	Regulation of substrate activity
WO2000053171A1 (en)	1999-03-05	2000-09-14	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
EP1228061A4 (en)	1999-11-12	2004-12-15	Guilford Pharm Inc	DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS
WO2001062266A2 (en)	2000-02-25	2001-08-30	Novo Nordisk A/S	Use of dpp-iv inhibitors for the treatment of diabetes
JP2003528135A (ja) *	2000-03-31	2003-09-24	プロバイオドラッグアーゲー	糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
US6573096B1 (en)	2000-04-01	2003-06-03	The Research Foundation At State University Of New York	Compositions and methods for inhibition of cancer invasion and angiogenesis
DE10025464A1 (de)	2000-05-23	2001-12-06	Inst Medizintechnologie Magdeb	Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US7785810B2 (en)	2000-09-09	2010-08-31	The Research Foundation Of State University Of New York	Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
CA2424600C (en) *	2000-10-06	2008-12-02	Tanabe Seiyaku Co., Ltd.	Aliphatic nitrogenous five-membered ring compounds

2002
- 2002-06-27 AT AT02758280T patent/ATE349435T1/de not_active IP Right Cessation
- 2002-06-27 CN CNA028284070A patent/CN1622941A/zh active Pending
- 2002-06-27 CA CA002479812A patent/CA2479812A1/en not_active Abandoned
- 2002-06-27 PL PL02372316A patent/PL372316A1/pl not_active Application Discontinuation
- 2002-06-27 CZ CZ2004973A patent/CZ2004973A3/cs unknown
- 2002-06-27 UA UA20040907210A patent/UA76309C2/uk unknown
- 2002-06-27 SI SI200230479T patent/SI1480961T1/sl unknown
- 2002-06-27 MX MXPA04008278A patent/MXPA04008278A/es active IP Right Grant
- 2002-06-27 SK SK362-2004A patent/SK3622004A3/sk unknown
- 2002-06-27 BR BR0215622-9A patent/BR0215622A/pt not_active IP Right Cessation
- 2002-06-27 PT PT02758280T patent/PT1480961E/pt unknown
- 2002-06-27 IL IL16362902A patent/IL163629A0/xx unknown
- 2002-06-27 DE DE20220238U patent/DE20220238U1/de not_active Expired - Lifetime
- 2002-06-27 DE DE60217186T patent/DE60217186T2/de not_active Expired - Fee Related
- 2002-06-27 KR KR10-2004-7013493A patent/KR20040095241A/ko not_active Ceased
- 2002-06-27 AU AU2002325278A patent/AU2002325278A1/en not_active Abandoned
- 2002-06-27 JP JP2003571262A patent/JP2005527504A/ja active Pending
- 2002-06-27 DK DK02758280T patent/DK1480961T3/da active
- 2002-06-27 NZ NZ534877A patent/NZ534877A/en unknown
- 2002-06-27 HU HU0600057A patent/HUP0600057A2/hu unknown
- 2002-06-27 EA EA200401062A patent/EA007434B1/ru not_active IP Right Cessation
- 2002-06-27 ES ES02758280T patent/ES2278944T3/es not_active Expired - Lifetime
- 2002-06-27 EP EP02758280A patent/EP1480961B1/en not_active Expired - Lifetime
- 2002-09-16 US US10/244,347 patent/US6946480B2/en not_active Expired - Fee Related
2004
- 2004-02-13 US US10/779,158 patent/US7060719B2/en not_active Expired - Lifetime
- 2004-08-25 BG BG108857A patent/BG108857A/xx unknown
- 2004-08-26 ZA ZA200406813A patent/ZA200406813B/xx unknown
- 2004-09-24 NO NO20044038A patent/NO20044038L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE20220238U1 (de)	2003-05-08
MXPA04008278A (es)	2005-09-20
EP1480961B1 (en)	2006-12-27
US7060719B2 (en)	2006-06-13
EP1480961A1 (en)	2004-12-01
ATE349435T1 (de)	2007-01-15
ZA200406813B (en)	2006-06-28
US20040167191A1 (en)	2004-08-26
HK1067120A1 (en)	2005-04-01
SI1480961T1 (sl)	2007-06-30
EA007434B1 (ru)	2006-10-27
JP2005527504A (ja)	2005-09-15
US6946480B2 (en)	2005-09-20
AU2002325278A1 (en)	2003-09-09
DE60217186T2 (de)	2007-09-27
KR20040095241A (ko)	2004-11-12
ES2278944T3 (es)	2007-08-16
NO20044038L (no)	2004-09-28
CZ2004973A3 (cs)	2004-12-15
UA76309C2 (en)	2006-07-17
CN1622941A (zh)	2005-06-01
BR0215622A (pt)	2004-12-07
NZ534877A (en)	2006-05-26
US20030162820A1 (en)	2003-08-28
PT1480961E (pt)	2007-02-28
CA2479812A1 (en)	2003-09-04
DE60217186D1 (de)	2007-02-08
SK3622004A3 (sk)	2005-02-04
DK1480961T3 (da)	2007-05-07
IL163629A0 (en)	2005-12-18
HUP0600057A2 (en)	2006-05-29
BG108857A (en)	2005-12-30
EA200401062A1 (ru)	2005-02-24

Legal Events

Date	Code	Title	Description
2009-12-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
SI1480961T1 (sl)	2007-06-30	Inhibitorji dpiv na osnovi glutaminila
NO20030895D0 (no)	2003-02-26	Ny anvendelse av dipeptidyl peptidase IV inhibitorer
YU84603A (sh)	2006-03-03	Novi inhibitori tirozin kinaze
AP1860A (en)	2008-07-02	Aryl fused azapolycyclic compounds.
GB0220187D0 (en)	2002-10-09	Organic compounds
GB0121033D0 (en)	2001-10-24	Organic compounds
WO2004013120A8 (en)	2005-04-14	Novel benzodioxoles
MY140693A (en)	2010-01-15	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200504034A (en)	2005-02-01	Therapeutic agents
MY142915A (en)	2011-01-31	Rho-kinase inhibitors
TW200510334A (en)	2005-03-16	Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MXPA05009157A (es)	2005-10-20	Pirrolopirimidinas espiro-sustituidas.
SI1696905T1 (sl)	2008-08-31	Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
TW200611699A (en)	2006-04-16	Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
DE602004011394D1 (en)	2008-03-06	Thiazolderivate
ZA9810735B (en)	1999-05-31	Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
TW200635903A (en)	2006-10-16	Therapeutic agents
TW200502221A (en)	2005-01-16	Novel lactams and uses thereof
TW200630374A (en)	2006-09-01	Thiazolyldihydroindazoles
MY129491A (en)	2007-04-30	Hydrazono-malonitriles
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
PL1765816T3 (pl)	2010-08-31	Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych
MY128241A (en)	2007-01-31	Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MXPA05007607A (es)	2005-09-30	Inhibidores amida y ester de la metaloproteinasa de matriz.
TW200509933A (en)	2005-03-16	Therapeutic agents